

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health (and subsidiaries)			
<b>2. Address</b> Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>			
<b>3. Principal place of business (if different than line 2)</b> City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>			
<b>4a. Contact Name</b> Mrs. <u>Shannon Penberthy</u>	<b>b. Telephone Number</b> <u>2027723504</u>	<b>c. E-mail</b> <u>shannon.penberthy@cvshealth.com</u>	<b>5. Senate ID#</b> <u>302778-12</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health (and subsidiaries)			<b>6. House ID#</b> <u>394420000</u>

**TYPE OF REPORT** 8. Year 2024 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center"><b>12. Lobbying</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>3,210,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy Date 4/22/2024 5:37:14 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to drug pricing transparency, women's health, and COVID-19 testing, vaccination and treatment.  
 H.R. 1770, The Equitable Community Access to Pharmacist Services Act  
 S. 2477, The Equitable Community Access to Pharmacist Services Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to the corporate tax rate.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program.

S. 1339 – Pharmacy Benefit Manager Reform Act of 2023  
 S. 1967 – Patients Before Middlemen Act of 2023  
 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act  
 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act  
 H.R. 2679 – Pharmacy Benefit Manager Accountability Act of 2023  
 H.R. 3285 – Fairness for Patient Medications Act  
 H.R. 1613 – Drug Price Transparency in Medicaid Act of 2023  
 H.R. 3561 – Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023  
 H.R. 5378 - Lower Costs, More Transparency Act  
 H.R. 2880 – Protecting Patients Against PBM Abuses Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Nicole	Burda			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

Issues related to employer, small group and individual insurance markets.  
 H.R. 6283 – Delinking Revenue from Unfair Gouging Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Robert	Butora			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Issues related to organized retail crime and consumer safety.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

\_\_\_\_\_

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
<b>1</b>	_____	_____	<b>3</b>	_____	_____
<b>2</b>	_____	_____	<b>4</b>	_____	_____

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address City	State/Province	Zip	Country	City State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address City	State/Province	Country			
				City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health (and subsidiaries)	
<b>2. Address</b> Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>	
<b>3. Principal place of business (if different than line 2)</b> City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>	
<b>4a. Contact Name</b> Mrs. <u>Shannon Penberthy</u>	<b>b. Telephone Number</b> <u>2027723504</u> <b>c. E-mail</b> <u>shannon.penberthy@cvshealth.com</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health (and subsidiaries)	<b>5. Senate ID#</b> <u>302778-12</u> <b>6. House ID#</b> <u>394420000</u>

**TYPE OF REPORT**8. Year 2024 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31) 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity **INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13**

<p align="center"><b>12. Lobbying</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSE</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>2,470,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature Digitally Signed By: Shannon Penberthy

Date \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to retail pharmacy, drug pricing, and women's health.  
 H.R. 1770, The Equitable Community Access to Pharmacist Services Act  
 S. 2477, The Equitable Community Access to Pharmacist Services Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to the corporate tax rate.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program.

S. 1339 – Pharmacy Benefit Manager Reform Act of 2023  
 S. 1967 – Patients Before Middlemen Act of 2023  
 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act  
 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act  
 H.R. 2679 – Pharmacy Benefit Manager Accountability Act of 2023  
 H.R. 3285 – Fairness for Patient Medications Act  
 H.R. 1613 – Drug Price Transparency in Medicaid Act of 2023  
 H.R. 3561 – Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023  
 H.R. 5378 - Lower Costs, More Transparency Act  
 H.R. 2880 – Protecting Patients Against PBM Abuses Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Nicole	Burda			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

Issues related to employer, small group and individual insurance markets.  
 S. 1542/H.R. 6283 - Delinking Revenue from Unfair Gouging Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Robert	Butora			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Issues related to organized retail crime and consumer safety.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

\_\_\_\_\_

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name Last Name Suffix First Name Last Name Suffix

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

\_\_\_\_\_

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	
	City				

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	City	State/Province			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health (and subsidiaries)			
<b>2. Address</b> Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>			
<b>3. Principal place of business (if different than line 2)</b> City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>			
<b>4a. Contact Name</b> Mrs. <u>Shannon Penberthy</u>	<b>b. Telephone Number</b> <u>2027723504</u>	<b>c. E-mail</b> <u>shannon.penberthy@cvshealth.com</u>	<b>5. Senate ID#</b> <u>302778-12</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health (and subsidiaries)			<b>6. House ID#</b> <u>394420000</u>

**TYPE OF REPORT** 8. Year 2024 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center"><b>12. Lobbying</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSE</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,520,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

**Signature** Digitally Signed By: Shannon Penberthy

**Date** 10/21/2024  
5:58:25 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to retail pharmacy, drug pricing, and women's health.  
 H.R. 1770, The Equitable Community Access to Pharmacist Services Act  
 S. 2477, The Equitable Community Access to Pharmacist Services Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to the corporate tax rate.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program.

S. 1339 - Pharmacy Benefit Manager Reform Act of 2023  
 S. 1967 - Patients Before Middlemen Act of 2023  
 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act  
 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act  
 H.R. 2679 - Pharmacy Benefit Manager Accountability Act of 2023  
 H.R. 3285 - Fairness for Patient Medications Act  
 H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023  
 H.R. 3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023  
 H.R. 5378 - Lower Costs, More Transparency Act  
 H.R. 2880 - Protecting Patients Against PBM Abuses Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Nicole	Burda			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

Issues related to employer, small group and individual insurance markets.  
 S. 1542/H.R. 6283 - Delinking Revenue from Unfair Gouging Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Robert	Butora			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Issues related to organized retail crime and consumer safety.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

\_\_\_\_\_

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1	_____	_____	3	_____	_____
2	_____	_____	4	_____	_____

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)		
	Street Address						
	City	State/Province	Zip	Country	City	State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**1** **2** **3**

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address					
	City	State/Province	Country	City		%
				State	Country	

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

**1** **3** **5**  
**2** **4** **6**

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health (and subsidiaries)			
<b>2. Address</b> Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>			
<b>3. Principal place of business (if different than line 2)</b> City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>			
<b>4a. Contact Name</b> Mrs. <u>Shannon Penberthy</u>	<b>b. Telephone Number</b> <u>2027723504</u>	<b>c. E-mail</b> <u>shannon.penberthy@cvshealth.com</u>	<b>5. Senate ID#</b> <u>302778-12</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health (and subsidiaries)			<b>6. House ID#</b> <u>394420000</u>

**TYPE OF REPORT** 8. Year 2024 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center"><b>12. Lobbying</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>2,040,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy Date \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to retail pharmacy, drug pricing, and women's health.  
 H.R. 1770, The Equitable Community Access to Pharmacist Services Act  
 S. 2477, The Equitable Community Access to Pharmacist Services Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to the corporate tax rate.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program.

S. 1339 – Pharmacy Benefit Manager Reform Act of 2023  
 S. 1967 – Patients Before Middlemen Act of 2023  
 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act  
 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act  
 H.R. 2679 – Pharmacy Benefit Manager Accountability Act of 2023  
 H.R. 3285 – Fairness for Patient Medications Act  
 H.R. 1613 – Drug Price Transparency in Medicaid Act of 2023  
 H.R. 3561 – Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023  
 H.R. 5378 - Lower Costs, More Transparency Act  
 H.R. 2880 – Protecting Patients Against PBM Abuses Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Nicole	Burda			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

Issues related to employer, small group and individual insurance markets.  
 S. 1542/H.R. 6283 - Delinking Revenue from Unfair Gouging (DRUG) Act  
 H.R. 10455 - To direct the Secretary of Health and Human Services to establish the Health Sector Cybersecurity Coordination Center, and for other purposes. Issues related to pharmacy benefit managers.  
 H.R. 10545 - the American Relief Act, 2025. Issues related to pharmacy benefit managers.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Robert	Butora			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Joy	McGlaun			<input type="checkbox"/>
Yujin	Lee			<input type="checkbox"/>
Rob	Butora			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>
Kaitlyn	Lane			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Issues related to organized retail crime and consumer safety.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Robert	Warbinton			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

\_\_\_\_\_

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1 Yujin	Lee		2		

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

\_\_\_\_\_

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	City	State/Province	Zip Country	

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

---

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	City	State/Province Country			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

---

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------